FDA 483 - Amgen, Inc. - March 13, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Amgen, Inc. in Thousand Oaks, CA, was cited for significant deficiencies across its manufacturing and quality control operations. Observations included failures in preventing microbiological contamination during sterile filling, inadequate investigation of discrepancies in visual inspection qualification records, and deficient microbial examination of in-process materials. Additionally, the firm lacked proper systems and training to ensure compliance with DSCSA verification requirements.
ID · f158a248-7fa2-44df-9ef9-74b5f972894b